Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

1.490 +0.010 (+0.68%)

Delayed Quote Updated: 11:49 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024 ↗

August 12, 2024

ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

August 12, 2024

From Enveric Biosciences

Via Business Wire

Why Is Imunon (IMNN) Stock Up 259% Today? ↗

July 30, 2024

Imunon stock is up on Tuesday with heavy trading of IMNN shares after posting positive results from a Phase 2 clinical trial.

Via InvestorPlace

Why Is Ekso Bionics (EKSO) Stock Down 15% Today? ↗

July 30, 2024

Ekso Bionics stock is down on Tuesday as investors in the company react to its lackluster earnings report for the second quarter of the year.

Via InvestorPlace

Why Is Enveric Biosciences (ENVB) Stock Up 18% Today? ↗

July 30, 2024

Enveric Biosciences stock is up on Tuesday with heavy trading of ENVB shares despite a lack of news from the company this morning.

Via InvestorPlace

Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 30, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

July 30, 2024

Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning!

Via InvestorPlace

Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗

July 30, 2024

Via Benzinga

Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally ↗

July 25, 2024

Via Benzinga

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

July 25, 2024

From Enveric Biosciences

Via Business Wire

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

July 15, 2024

From Enveric Biosciences

Via Business Wire

New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies ↗

July 11, 2024

Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological disorders, including depression and anxiety.

Via Benzinga

Topics Intellectual Property

Enveric Biosciences Announces Patent Granted for Drug Candidate

July 10, 2024

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

June 25, 2024

From Enveric Biosciences

Via Business Wire

Enveric Biosciences to Participate in BIO International Convention 2024

May 30, 2024

From Enveric Biosciences

Via Business Wire

ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q1 2024 ↗

May 20, 2024

ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand ↗

May 16, 2024

Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the...

Via Benzinga

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

May 15, 2024

From Enveric Biosciences

Via Business Wire

Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate ↗

May 14, 2024

Via Benzinga

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

May 14, 2024

From Enveric Biosciences

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 08, 2024

Via Benzinga

Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods ↗

May 08, 2024

The news of the licensee deal comes on the heels of the DEA's move to reschedule marijuana, one source of cannabinoids, as a Schedule III controlled substance.

Via Benzinga

Topics Cannabis

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

May 08, 2024

From Enveric Biosciences

Via Business Wire

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗

April 17, 2024

Via Benzinga

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

April 03, 2024

Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 03, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 02, 2024

Via Benzinga

ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023 ↗

April 01, 2024

ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗

March 29, 2024

Via Benzinga

Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth ↗

March 27, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.